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ess: KADITIA@hotmail.cSummary Vascular endothelial growth factor (VEGF) may be one of the
pathophysiologic links in the association between obstructive sleep apnea-hypopnea
and cardiovascular disease. Morning serum VEGF levels are increased in children with
obstructive sleep apnea. However, release of VEGF by platelets and leukocytes
during blood clotting may affect its concentration in serum. In the present study,
VEGF levels were measured in children with and without habitual snoring using
plasma specimens. Evening and morning plasma VEGF concentrations were
determined in: (i) 20 children with habitual snoring and apnea–hypopnea index
(AHI)X5 episodes/h (median age 5; range 1.9–13 years); (ii) 55 children with snoring
and AHIo5 episodes/h (median age 6; 2–13 years); and (iii) 25 controls without
snoring (median age 6.5; 3–13 years). No differences were identified between the
three study groups regarding evening [median 2.5 (range 2.5–174.5) versus 22.5
(2.5–159.4) versus 26.8 (2.5–108) pg/mL; P40:05] and morning VEGF levels [median
7.7 (range 2.5–120.5) versus 25.1 (2.5–198.4) versus 48.4 (2.5–147.7) pg/mL;
P40:05]. AHI and % sleep time with oxygen saturation of hemoglobin less than
90% were not significant predictors of log-transformed morning VEGF concentrations
(P40:05). In summary, both evening and morning plasma VEGF levels were similar in
children with obstructive sleep-disordered breathing of variable severity and inElsevier Ltd. All rights reserved.
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A.G. Kaditis et al.836controls without snoring. VEGF may not play an important pathophysiologic role in
all cases of obstructive sleep-disordered breathing in childhood.
& 2005 Elsevier Ltd. All rights reserved.Introduction
Significant correlations between obstructive sleep-
disordered breathing and cardiovascular disease
have been reported in adults. Even mild increases
in the apnea–hypopnea index (AHI) (1–10 episodes/
h) have been associated with higher risk for coronary
artery disease, congestive heart failure and stroke.1
Among other variables, systemic hypertension,2
chronic inflammation and metabolic disturbances,3,4
endothelial dysfunction5 and changes in myocardial
structure and function5 have been implicated in the
interaction between cardiovascular disease and
sleep apnea. Similar abnormalities have been
described in habitually snoring children.6–10
Vascular endothelial growth factor (VEGF), a
cytokine stimulating angiogenesis,11 may contri-
bute to the process of atherogenesis and develop-
ment of cardiovascular disease.12–15 Its morning
concentrations are increased in adults with ob-
structive sleep apnea–hypopnea.16–18 Treatment of
sleep apnea with nasal continuous positive airway
pressure or of the associated hypoxemia with
administration of oxygen have been accompanied
by a significant decrease in morning values of
VEGF.18,19
To our knowledge, there is only one report on
morning serum levels of VEGF in children with
obstructive sleep-disordered breathing.20 Higher
levels of VEGF have been detected in children with
sleep apnea (apnea index45 episodes/h) than in
control subjects.20 Nevertheless, platelets and
leukocytes release VEGF during the process of
blood clotting and for this reason measured con-
centrations of the factor are higher in serum
samples than in plasma samples.20,21 Furthermore,
VEGF concentrations are not consistently increased
in all adults with obstructive sleep-disordered
breathing; in a recent study by Valipour and
colleagues,22 similar plasma VEGF levels were
reported in adult participants with and without
obstructive sleep apnea. The aim of the present
investigation was to measure evening and morning
plasma VEGF levels in children with obstructive
sleep-disordered breathing of variable severity
and in controls without snoring. We hypothesized
that severity of sleep-disordered breathing is
related to morning plasma VEGF concentration.
To our knowledge, this is the first study assessing
both evening and morning VEGF levels in children
with sleep apnea.Patients and methods
Study design
Consecutive children, who were referred to the
Sleep Disorders Laboratory because of habitual
snoring (more than three nights/week) present for
at least 6 months, were recruited in the study.
Healthy children without history of snoring that
were admitted to the pediatric inpatient service for
constipation or functional abdominal pain were also
recruited as controls. Children were excluded from
participation in the study if they had: (1) symptoms
or signs of acute or chronic inflammation; (2) lung
disease associated with hypoxemia; (3) cardiovas-
cular disease; and (4) neuromuscular or genetic
disorders.
The study protocol was approved by the Ethics
Committee of the Larissa University Hospital.
Informed consent was obtained from parents and
child’s assent from subjects older than 7 years.
Since January 2003, more than 200 pediatric
polysomnograms are performed in the Sleep Dis-
orders Laboratory of the Larissa University Hospital
annually. None of the subjects in the present
investigation were included in other research
projects that were carried out in our center.23,24
Parents were interviewed and information about
symptoms of sleep-disordered breathing and about
past medical history was collected. All participants
underwent a physical examination. Polysomno-
grams were performed overnight in the Sleep
Disorders Laboratory for all children with snoring
but not for controls. The Alice-4 computerized
system (Healthdyne, Marietta, GA, USA) was used.
Sleep stages and arousals were determined using
standard criteria.25,26 Obstructive apnea was de-
fined as the presence of chest/abdominal wall
motion in the absence of airflow for at least two
breaths in duration.27 Hypopnea was: (1) a reduc-
tion in the airflow signal amplitude of at least 50%
compared to baseline; (2) in the presence of chest/
abdominal wall motion; and (3) associated with
oxygen desaturation of hemoglobin equal to or
greater than 4% or with an arousal.27 AHI, respira-
tory movement/arousal index, oxygen desaturation
of hemoglobin index, oxygen saturation of hemo-
globin nadir and % sleep time with oxygen satura-
tion of hemoglobino90% were calculated as
described previously.23,24
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Since platelets and leukocytes release VEGF during
blood clotting,21 measurements were carried out in
plasma and not serum specimens. Evening and
morning blood samples were collected into glass
tubes containing EDTA, were immediately centri-
fuged, and the supernatant (platelet-free plasma)
was aliquoted and frozen at 70 1C until assay.
A commercially available ELISA kit for the in vitro
determination of human VEGF-165 and VEGF-121
was used (Human VEGF; BioSource Europe S.A.,
Nivelles, Belgium). The minimum VEGF concentra-
tion detected by this assay is 5 pg/mL. Intra-assay
coefficients of variation are 5.5% at 87.4 pg/mL,
3.7% at 345 pg/mL and 4.9% at 938 pg/mL.Data analysis and statistics
Three groups of subjects were studied: (1) children
with habitual snoring and AHIX5 episodes/h8;
(2) children with habitual snoring and AHIo5
episodes/h; and (3) control subjects without snor-
ing. There have been no previous studies in children
with sleep-disordered breathing reporting VEGF
concentrations in plasma specimens. Therefore, it
is not possible to calculate the sample size that is
required to detect a significant difference in VEGF
levels between subjects with an AHIX5 episodes/h
and subjects with an AHIo5 episodes/h.
Overnight change in VEGF levels was defined as:
morning plasma VEGF concentrationevening plas-
ma VEGF concentration. Values below the lowest
detection limit of the method (5 pg/mL) were
considered equal to 2.5 pg/mL. The Kruskal–Wallis
test was applied to compare the three groups
regarding continuous characteristics. Comparisons
between groups for categorical characteristics
were carried out by the w2-test (Yate’s correction).
Spearman’s correlation was used to assess the
association of morning VEGF values with body mass
index and polysomnography indices. To adjust body
mass index for the effect of age and gender,
relative body mass index [(absolute value/value
of 50th percentile for age and gender) 100] was
calculated using standard growth curves.28 To
identify independent predictors of morning VEGF
values, multiple linear regression analysis was
performed (SPSS 10.0; SPSS, Chicago, IL, USA).
Morning VEGF values were log-transformed prior to
the analysis so that they were normally distributed.
Log-transformed morning VEGF concentration was
the dependent variable and AHI (or % sleep time
with oxygen saturation of hemoglobin less than90%), age, gender and relative body mass index
were entered as independent variables.Results
Patient characteristics and results of
polysomnography
Eighty-five children with and 34 children without
snoring were invited to participate in the study.
Parents of 15 children (eight snorers and seven non-
snorers) declined participation to the study and
four more subjects (two snorers and two non-
snorers) were excluded due to symptoms of upper
respiratory tract infection. A total of 100 subjects
were finally recruited in the study: 20 children with
habitual snoring and AHIX5 episodes/h (median
age 5; range 1.9–13 years); 55 subjects with snoring
and AHIo5 episodes/h (median age 6; range 2–13
years); and 25 controls without snoring (median age
6.5; range 3–13 years). Frequency of sleep-dis-
ordered breathing symptoms in the three study
groups, and polysomnography indices in children
with an AHIX5 episodes/h or AHIo5 episodes/h are
summarized in Table 1.
VEGF measurements
The study groups were similar regarding variables
that may affect VEGF values (Table 2). No sig-
nificant differences were identified between groups
regarding evening or morning VEGF values
(P40:05) (Table 2 and Fig. 1). Mean (7SD) morning
VEGF values were: 35.4742.5 pg/mL in children
with snoring and AHIX5 episodes/h; 46.7754.5 pg/
mL in subjects with snoring and AHIo5 episodes/h;
and 50.7737.1 pg/mL in controls without snoring.
The overnight change in VEGF levels in children
with habitual snoring was also similar in: snorers
with AHIX5 episodes/h (median 0 pg/mL; range
94.7 to 72.6); snorers with AHIo5 episodes/h
(median 0 pg/mL; range 108.6 to 138.2); and
controls without snoring (median 10.4 pg/mL;
range 67.2 to 101.6) (P40:05).
Morning VEGF levels were not correlated with:
(i) relative body mass index (r ¼ 0:04; P40:05);
(ii) AHI (r ¼ 0:15; P40:05); (iii) respiratory
arousal index (r ¼ 0:17; P40:05); (iv) oxygen
saturation of hemoglobin nadir (r ¼ 0:04;
P40:05); (v) oxygen desaturation of hemoglobin
index (r ¼ 0:2; P40:05); or (vi) % sleep time with
oxygen saturation of hemoglobin less than 90%
(r ¼ 0:06; P40:05). When multiple linear regres-
sion analysis was carried out, AHI (or % sleep time
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Table 1 Summary statistics for symptoms of sleep-disordered breathing and polysomnography indices in the
three study groups.
Snorers with AHIX5
episodes/h (n ¼ 20)
Snorers with AHIo5
episodes/h (n ¼ 55)
Controls without
snoring (n ¼ 25)
Snoring 43 nights/week 20 (100%) 55 (100%) 0 (0%)
Apnea 43 nights/week 16 (80%) 28 (51%) 0 (0%)
Difficulty breathing 43 nights/week 17 (85%) 37 (67%) 0 (0%)
Apnea index (episodes/h) 2.9 0.6 —
(0.7–16.7) (0–2.3)
Apnea–hypopnea index (episodes/h) 9.6 1.9 —
(5–45.4) (0.2–4.9)
Respiratory movement/arousal index
(episodes/h)
2.2 0.7 —
(0.7–16.3) (0–2.2)
Oxygen desaturation of hemoglobin
(44%) index (episodes/h)
9.4 1.5 —
(3.3–49) (0–4.4)
SaO2 nadir (%) 84 91 —
(69–91) (81–94)
% Sleep time with SaO2o90% 0.3 0 —
(0–5.6) (0–0.26)
Continuous variables are expressed as median (range).
AHI: Apnea–hypopnea index.
Table 2 Summary statistics and significance of comparisons between the three study groups regarding vascular
endothelial growth factor (VEGF) values and factors that may affect these values.
Snorers with AHIX5
episodes/h (n ¼ 20)
Snorers with AHIo5
episodes/h (n ¼ 55)
Controls without
snoring (n ¼ 25)
Age (years) 5 6 6.5
(1.9–13) (2–13) (3–13)
Gender, female (%) 9 (45%) 26 (47.3%) 11 (44%)
Relative BMI (%) 102.5 115.5 105.9
(71.5–147.3) (86.2–180.8) (78.2–184.6)
Evening VEGF (pg/mL) 2.5 22.5 26.8
(2.5–174.5) (2.5–159.4) (2.5–108)
Morning VEGF (pg/mL) 7.7 25.1 48.4
(2.5–120.5) (2.5–198.4) (2.5–147.7)
Continuous variables are presented as median (range).
P40:05 for all comparisons between study groups.
BMI: Body mass index.
A.G. Kaditis et al.838with oxygen saturation of hemoglobin less than
90%), age, gender and relative body mass index
were not significant predictors of log-transformed
morning VEGF values.Discussion
In the present investigation, evening and morning
plasma VEGF levels were measured in children with
obstructive sleep-disordered breathing of variableseverity and in controls without snoring. In accor-
dance with findings reported in adults with ob-
structive sleep apnea by Valipour and colleagues,22
similar levels of VEGF were identified in the three
study groups that were not correlated with severity
of sleep-disordered breathing. No differences were
noted in the overnight change of VEGF values
between the three groups of participants.
Obstructive sleep apnea–hypopnea in adults has
been correlated with increased frequency of
cardiovascular disease and various etiologic links
have been proposed to explain this association.1–5
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Figure 1 Boxplots of morning plasma vascular endothe-
lial growth factor (VEGF) levels (pg/mL) in: (i) children
with habitual snoring and apnea–hypopnea index
(AHI)X5 episodes/h (n ¼ 20); (ii) subjects with habitual
snoring and AHIo5 episodes/h (n ¼ 55); and (iii) controls
without snoring (n ¼ 25). VEGF values are similar in the
three study groups (P40:05). Horizontal bars represent
median VEGF levels; upper and lower parts of the
boxplots are the 25th and 75th percentile values;
whiskers represent highest and lowest VEGF levels and
triangles are outlier values.
VEGF and snoring 839Persistent long-term increase of VEGF concentra-
tions may be one of the factors participating in the
process of atherogenesis and development of
cardiovascular disease in subjects with obstructive
sleep apnea–hypopnea and nocturnal hypoxe-
mia.12,13,16–20 Nevertheless, increased VEGF levels
are not identified in all adults with sleep apnea.22
Serum VEGF levels are similar in healthy adults
and children.20,29 VEGF is a key regulator in
angiogenesis, and hypoxia is a major stimulus for
its synthesis.30,31 Administration of 2 L/min of
oxygen overnight to adults with sleep apnea and
hypoxemia was associated with a significant de-
crease in serum levels of VEGF.19 Gozal and
colleagues20 reproduced findings of studies with
adult participants in 20 children with obstructive
sleep apnea (apnea index45 episodes/h). Children
with an apnea index45 episodes/h had higher
morning serum VEGF concentrations than controls
with apnea indexo5 episodes/h (n ¼ 21) (2207112
versus 66723 pg/mL). VEGF levels were correlated
with both respiratory disturbance index and dura-
tion of nocturnal hypoxemia, which is in contrast to
our findings (absence of correlation with polysom-
nography indices).When comparing the present report with the
investigation by Gozal and colleagues,20 mean
(7SD) morning VEGF concentrations in children
with sleep-disordered breathing of the former
study seem to be lower than VEGF levels in subjects
of the latter study. These different values could be
due at least partially to measuring plasma VEGF
levels in the current study as opposed to measuring
serum levels in the previous report.20,21 More
subjects were recruited in the present series than
in the investigation by Gozal and colleagues (100
versus 41), whereas in both reports age and female-
to-male ratio of participants were similar. Of note,
children with snoring in the investigation by Gozal
and colleagues had more severe and prolonged
nocturnal hypoxemia. This study characteristic
could possibly explain the difference in VEGF
concentrations between subjects with obstructive
sleep apnea and controls in the Gozal and collea-
gues report and the lack of such a difference
between participants with AHIX5 episodes/h and
controls in the current study.
No correlation was identified between morning
VEGF levels and relative body mass index in this
investigation and such a relationship was not
described in the previously published pediatric
report.20 However, VEGF concentration was signifi-
cantly related to body mass index in some,18,22 but
not all17 reports including adults with sleep apnea.
A potential limitation of the current study is that
controls without snoring did not undergo polysom-
nography because this was not acceptable to the
majority of parents. We cannot exclude the
possibility that more participants had to be
included for identifying a significant relationship
between nocturnal hypoxemia and morning VEGF
levels, although we recruited far more children
compared to the study by Gozal and colleagues.20
In conclusion, no significant association was
identified between morning plasma VEGF levels
and severity of obstructive sleep-disordered
breathing in children with habitual snoring. In
accordance with findings in adults,22 VEGF may
not play an important pathophysiologic role in all
cases of obstructive sleep-disordered breathing in
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